Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation.

The prescribing information says: "Administer full myeloablative conditioning with busulfan or another myeloablative conditioning regimen prior to treatment with CASGEVY." It also states that patients undergo hematopoietic stem cell mobilization and apheresis before manufacturing, and that CASGEVY is given after conditioning.

"Myeloablative conditioning with busulfan must be administered before infusion of LYFGENIA. Busulfan should be administered via a central venous line." The dosing section specifies: "The recommended initial dose of busulfan is 3.2 mg/kg/day for 4 consecutive days as a 3-hour infusion for a total of 4 doses… To achieve myeloablation, the busulfan target AUC is 5000 (range 4400 to 5400) μM*min for a once daily dosing regimen." It also reiterates under "Myeloablative Conditioning": "Myeloablative conditioning with busulfan must be administered before infusion of LYFGENIA."

CD34+ HSPCs were collected from patients by apheresis…CTX001 was manufactured from these CD34+ cells by editing with CRISPR-Cas9…Patients received single-agent, pharmacokinetically adjusted busulfan myeloablation before the infusion of CTX001. After the administration of CTX001, both patients had early, substantial, and sustained increases in fetal hemoglobin levels…with durable engraftment…Initial results…have shown…elimination of vaso-occlusive episodes or need for transfusion.

Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Prior to treatment, a patients’ own stem cells are collected, and then the patient must undergo myeloablative conditioning (high-dose chemotherapy), a process that removes cells from the bone marrow so they can be replaced with the modified cells in Casgevy and Lyfgenia.

Therefore, myeloablative busulfan conditioning is typically used for autologous HSC gene therapy in SCD. Busulfan eliminates the patients’ HSCs and creates space in the bone marrow niche for efficient engraftment of gene-modified HSCs.

The review states that busulfan is a common conditioning agent for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies, and it discusses myeloablative busulfan regimens used in ex vivo gene-modified HSC studies, including exa-cel.

Under "Myeloablative Conditioning," the dosage guide states: "Myeloablative conditioning with busulfan must be administered before infusion of LYFGENIA." It further describes busulfan dosing: "The recommended initial dose of busulfan is 3.2 mg/kg/day for 4 consecutive days as a 3-hour infusion for a total of 4 doses… To achieve myeloablation, the busulfan target AUC is 5000 (range 4400 to 5400) μM*min for a once daily dosing regimen." It notes that these cells "must be collected from the patient and be cryopreserved prior to myeloablative conditioning."

Conventional myeloablative conditioning improves HSC engraftment by clearing the HSC niche…Busulfan is an alkylating agent that interferes with DNA replication…Therefore, myeloablative busulfan conditioning is typically used for autologous HSC gene therapy in SCD. While myeloablative conditioning maximizes HSC engraftment, it can cause severe side effects…Particularly in younger patients, there are long-term risks of infertility and secondary malignancies. Reduced-intensity conditioning with lower busulfan doses has been tested…however, lower vector copy numbers and therapeutic hemoglobin levels were seen. The gene-editing trial in SCD resulted in 86% editing…with adverse events associated with busulfan conditioning.

All received a single intravenous infusion of Casgevy after a conditioning regimen with busulfan. Two to seven days before the Casgevy infusion, the patient undergoes a myeloablative conditioning regimen to clear out unhealthy blood stem cells and make room for the new ones; this involves high-dose chemotherapy with an agent such as busulfan.

The safety profile was generally consistent with that expected from busulfan myeloablative conditioning and HSC transplant. The page also says the adverse event profile included events associated with busulfan myeloablative conditioning and treatment with CASGEVY.

The treatment pathway describes: "Prior to LYFGENIA infusion, patients will undergo full myeloablative conditioning followed by a 2-day minimum washout period." In the stepwise process, "Conditioning and washout" is listed before "Infusion", and the page highlights "The risks associated with mobilization and myeloablative conditioning agents" as part of counseling and planning for therapy.

Individuals from whom exa-cel is prepared receive single-agent busulfan myeloablation before receiving exa-cel in order to suppress the ability of bone marrow to produce native blood cells. The individuals are then infused with autologous exa-cel product consisting of over a million modified CD34+ HSPCs per kilogram of body weight.

Casgevy gene therapy treatment is a multistep process: blood stem cells are removed, genetically modified, and reinfused. Before the stem cells are reinfused, patients are treated with busulfan chemotherapy to ablate existing bone marrow cells so the genetically modified cells can engraft.

Both therapeutic approaches utilize ex vivo modification of autologous hematopoietic stem and progenitor cells. For CRISPR therapy, CD34+ cells are collected via apheresis, electroporated with the CRISPR-Cas9 system, and reinfused after myeloablative conditioning with busulfan.

Conventional autologous gene therapy protocols for sickle cell disease have largely relied on myeloablative conditioning with busulfan to maximize engraftment of gene-modified hematopoietic stem and progenitor cells. In addition to busulfan, another alkylating agent, melphalan has been used as a conditioning agent for gene therapy. However, melphalan lacks a validated pharmacokinetic dosing strategy and long-term safety data in this setting, so busulfan remains the standard. Novel approaches aim to reduce toxicity by using antibody-drug conjugates or targeted conditioning agents, but these are still investigational.

The CRISPR-Cas9 system is used to edit a person’s own stem cells outside the body, and the edited cells are given back to the patient. Before giving back the gene edited cells, patients will undergo a conditioning regimen to eliminate bone marrow stem cells. The conditioning regimen consists of high-dose chemotherapy, which helps to make room for the gene edited stem cells to grow when they are eventually transplanted back into the patient.

CASGEVY (exagamglogene autotemcel) is a one-time gene therapy treatment for people age 12 years or older with sickle cell disease or beta thalassemia. The hospital page identifies it as the approved gene therapy product used for these indications.

The product information notes regarding pre-transplant management: "Hydroxyurea: If administered after apheresis, discontinue hydroxyurea at least 2 days before myeloablative conditioning…" and in the dosing section specifies that patients receive "myeloablative conditioning with busulfan before infusion" of lovotibeglogene autotemcel.

The medication reference states that busulfan dosing is adjusted to a 4-day target cumulative exposure of 82 mg⋅h/L, indicating that busulfan is part of the standard CASGEVY conditioning regimen.

Describing the procedure, the article explains: "First, patients must undergo high-dose chemotherapy with an agent called busulfan to eliminate unhealthy blood stem cells and make room for the new ones in the bone marrow. Busulfan is given via an infusion directly into the bloodstream. This process, known as myeloablative conditioning, will occur over four consecutive days and must be completed a minimum of two days prior to Lyfgenia administration." It adds that "At least two days after myeloablative conditioning, the Lyfgenia will be thawed and prepared… then administered via a stem cell transplant as an intravenous… infusion."

A review of transplant regimens states: "Busulfan (Bu)-containing regimens are commonly used in myeloablative conditioning regimens before allogeneic hematopoietic cell transplantation (HCT)." It evaluates intravenous busulfan-based myeloablative conditioning and concludes that "HCT conditioning regimens using i.v. Bu Q6 or Q24 alone or in combination with Cy or Flu have similar outcomes in the myeloablative setting," underscoring busulfan’s role as a standard backbone of myeloablative conditioning.

Iron chelation therapy can be continued during mobilization but has to be discontinued 10 days prior to initiating busulfan chemotherapy. For current ex vivo gene therapy trials in sickle cell disease, myeloablative conditioning with busulfan is the predominant approach to prepare the bone marrow niche for autologous gene-modified HSPC infusion. The article outlines best practices for busulfan dosing, monitoring, and toxicity management in the context of gene therapy.

An analysis of conditioning practices notes: "Busulfan (Bu) is a key backbone of myeloablative conditioning (MAC) regimens in patients undergoing allogeneic stem cell transplant (ASCT)." The study focuses on "optimizing busulfan dosing in myeloablative conditioning" and emphasizes the central role of busulfan-based MAC in current transplant protocols.

Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo, CRISPR-Cas9 gene edited cell therapy approved for patients 12 years and older with sickle cell disease; the dosing discussion centers on pharmacokinetically-adjusted busulfan before infusion.

Treating sickle cell anemia with CRISPR involves an ex vivo procedure known as gene-edited cell therapy, where hematopoietic stem cells are extracted from the body, edited using CRISPR, and then reinfused after conditioning chemotherapy. Most current CRISPR sickle cell trials, such as CTX001 (Casgevy) and other autologous HSPC transplant approaches, require myeloablative conditioning—typically with busulfan—to create space in the bone marrow for the edited cells. New trials are beginning to explore reduced-intensity or alternative conditioning regimens, but these are not yet standard of care.

A clinical trial of allogeneic stem cell transplantation reports: "Myeloablative fractionated busulfan regimen results in low nonrelapse mortality without a higher relapse rate. This regimen is a viable myeloablative alternative for patients who receive a reduced intensity regimen because of age or comorbidity." The regimen involved "fractionated delivery of a myeloablative dose of Bu" in combination with fludarabine as a conditioning strategy.

A phase 2 study describes conditioning for acute myeloid leukemia: "Myeloablative dose of Busulfan and Fludarabine combined with in vivo T cell depletion is safe and effective conditioning for acute myeloid leukemia." The protocol uses a "myeloablative dose of Busulfan" as part of the conditioning backbone, illustrating ongoing reliance on busulfan-based myeloablative regimens.

The role of the conditioning regimen for autologous and ex vivo gene therapies is reviewed, with current datasets and clinical experience discussing different conditioning regimens used before reinfusion of edited cells.

Background clinical knowledge: Ex vivo gene-editing therapies for sickle cell disease, such as lovotibeglogene autotemcel, collect autologous hematopoietic stem cells, edit them outside the body, and then reinfuse them after myeloablative conditioning. Current approved CRISPR-based ex vivo therapies for sickle cell disease in the U.S. (e.g., Casgevy) use a busulfan-based myeloablative conditioning regimen before reinfusion, aligning with standard transplant practices, although future approaches under investigation aim to replace busulfan with less toxic or non-genotoxic conditioning agents.

Patients with sickle cell disease have been treated with ex vivo CRISPR-Cas9-based gene therapy approved for severe sickle cell disease, and the therapy’s safety profile was similar to that of myeloablative busulfan conditioning and autologous hematopoietic stem cell transplantation.

This coverage says a consensus is forming that busulfan conditioning remains a major issue in autologous stem cell transplant-based gene therapies, and that safer alternatives are being explored for sickle cell disease. It provides context that busulfan use is common, but not necessarily universal across future therapies.